The Intellectual Property & Science business of Thomson Reuters has announced the launch of Cortellis Data Fusion, an addition to the Thomson Reuters Cortellis suite, a comprehensive information solution for drug discovery and development. Cortellis Data Fusion utilises linked data technologies – frameworks that allow content to be shared across applications and enterprise or community boundaries – connecting users with data from internal proprietary systems as well as third-party resources to address Big Data challenges.
Big Data and the Needs of the Pharma Industry, a Thomson Reuters whitepaper surveying IT leaders within pharma, found that access to external content is the industry's top challenge around managing the ever-growing Big Data environment. Cortellis Data Fusion provides users with seamless access to internal and external content and the ability to aggregate, integrate and analyse large volumes of varied data through a single, user-friendly interface.
The faster and deeper insight from Cortellis Data Fusion is possible because content is parsed into manageable, actionable Little Data. There are inherent, intuitive data analytic links that enable users to discover unexpected associations, generate hypotheses and share novel ideas. The solution also employs enterprise information security architecture ensuring proprietary data and analyses remain safe.
Opportunities created by Cortellis Data Fusion are a result of the recent acquisition by Thomson Reuters of Entagen, an industry-leader in providing semantic search/navigation software and custom development services to large pharma, biotech and laboratory automation companies.
